Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01969318

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01969318
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01969318. Randomized; quadruple masking; primary purpose prevention. Start 2012-03 (registry gives no type); primary completion 2012-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Intervention (Drug)
Placebo /Metformin
Intervention (Drug)
SP2086(50 mg q.d.)/Metformin
Intervention (Drug)
SP2086 (100 mg q.d.)/Metformin
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01969318
Content hash
71d3ccfb4f65ab7709350825040bde0afa81bdaab398a63737a782a761d82459